Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zhejiang Hisun to Raise $328 Million to Increase Capacity

publication date: Dec 4, 2013
Zhejiang Hisun Pharma will raise at least 2 billion RMB ($328 million) in a private placement. The company will offer up to 139.5 million new shares at a price not lower than 14.26 RMB per share (current price is 17.22 RMB). Hisun will use the money to build facilities for three projects: facilities for solid preparations and injections, solid preparation cancer treatments and the Phase II of its biopharmaceutical initiative. More details....

Stock Symbol: (SHA: 600267)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital